This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Recent Videos Related Content FDA to Evaluate Merck’s Doravirine, Islatravir Regimen for HIV-1 Killian Meara July 10th 2025 Article The FDA set a Prescription Drug User Fee Act (PDUFA) date of April 28, 2026.
The Immunization Action Coalition also has a travel vaccine section on its website with many resources. Depending on the pharmacy practice act for your state, you may or may not be able to provide all vaccinations recommended by the Advisory Committee on Immunization Practices. 2026 Edition. The Immunization Action Coalition.
"I think it's really important, as we move to 2026 and beyond, we figure out ways to help pharmacies ease that burden and diversify their business." There's going to be reimbursement pressures that pharmacies are faced with when it comes to script revenue," Flaugher said.
You just want to slash it, rip it out or attack it like an enemy target,” said Benjamin Zeskind, co-founder, CEO and president of Immuneering Corporation. To overcome that hurdle, Immuneering is testing an approach that slows cancer down rather than rushing to destroy it.
PQA is developing its next strategic plan, Blueprint PQA 2030, which will guide the organization’s work from 2026 through 2030. These emerging opportunities include immunizations, medication therapy management, and point-of-care testing. Welcome to Five For Friday!
SHOW MORE Administering influenza, COVID-19, and RSV immunizations at the same time may improve vaccine uptake. Patients should be informed that the 2025-2026 influenza vaccines will be trivalent, covering 2 influenza A strains (H1N1 and an updated H3N2) and 1 B/Victoria lineage strain, as the B/Yamagata lineage is no longer circulating.
The Advisory Committee on Immunization Practices (ACIP) discussed COVID-19 epidemiology and safety and efficacy for vaccination. HHS stated that healthy children and healthy pregnant women should be removed from the CDC’s recommended immunization schedule, but the CDC has different recommendations. 1 lineage, preferably with the LP.8.1
The legislation also supports the use of mobile manufacturing units, offering close-to-home treatment for patients too unwell to travel, or whose weakened immune systems mean hospital visits carry extra risk.
Mary Dzhuryan is a class of 2026 PharmD candidate at the USC Alfred E. Mehrnaz Razavi Vakhshoori is a class of 2026 PharmD candidate at the USC Alfred E. The recent application was granted both priority review and orphan drug designation. Mann School of Pharmacy and Pharmaceutical Sciences in Los Angeles.
Reduced immunity from COVID-19 precautions and low vaccination rates, especially among children and vulnerable groups, worsened the influenza season's impact. Systemic inequities, misinformation, and geographic disparities hindered vaccination efforts, with significant coverage gaps among racial and rural populations.
1-4 About the Author Sinem Yasil is a 2026 PharmD candidate at the South College School of Pharmacy in Knoxville, Tennessee. Apixaban, edoxaban, and rivaroxaban inhibit factor Xa, while dabigatran inhibits thrombin, achieving similar anticoagulant effects. 5 A CBC provides information on an individual’s hematologic status.
USP plans to continue expanding its advanced technology footprint into an additional 8,000 square foot laboratory in 2026. The Advanced Technologies Lab is the latest of USP’s investments in advanced manufacturing technologies. Learn more about USP’s supply chain solutions.
This hesitancy can lead to delayed vaccination or outright refusal, directly impacting population-level immunity and increasing the risk of widespread influenza outbreaks and associated complications. Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization.
For instance, the MFP is expected to affect approximately 10 drugs in 2026, with the list expanding annually, potentially creating a $22,000 monthly financial impact for average retail pharmacies.
“MP1032’s unique mechanism — modulating mitochondrial ROS in overactive immune cells — could transform long-term DMD management by slashing corticosteroid doses and side effects. Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
Nieto is a 2026 PharmD Candidate at the University of Connecticut School of Pharmacy in Storrs, CT. Literature—particularly, an analysis of 20,000 United States adults—suggests a higher risk of cardiovascular disease mortality in those who restricted eating to less than 8 hours per day; additional studies are needed to confirm these findings.
6 A new drug application (NDA) with the FDA and global regulators are expected to be filed by March 2026, according to the manufacturers. Impressively, over 95% of trial completers entered the ongoing long-term extension study, reflecting both tolerability and sustained interest among participants.
Merck said in the release that it anticipates ordering of clesrovimab-cfor to begin in July, with shipments being delivered before the start of the 2025-2026 RSV season. The therapy should not be given to infants with a history of serious hypersensitivity reactions to any of its ingredients.
Image Credit: Adobe Stock Images/Artur.com Key Takeaways Sanofi is shipping Beyfortus early to ensure strong supply for the 2025–2026 RSV season and avoid past shortages. For instance, an immunization program that was executed in Spain using Beyfortus reportedly reduced infant hospitalizations due to RSV by 69.0% June 9, 2025.
Find out more The Prescription Drug User Fee Act (PDUFA) action date is set for 5 June 2026. Reports LOA and PTSR Model - Mecbotamab Vedotin in Breast Cancer Data Insights The gold standard of business intelligence. It is being developed collaboratively by Arvinas and Pfizer as a potential monotherapy option.
In a vote of 5 to 1 on Thursday, members of the Advisory Committee on Immunization Practices (ACIP) voted to recommend against influenza vaccine containing the preservative thimerosal. 1,3 The day prior, ACIP took to discussions about COVID-1, which was highly awaited due to confusion surrounding the upcoming 2025-2026 respiratory season.
July 22, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook PsO is an immune-mediated disease characterised by rapid skin cell proliferation leading to inflamed plaques that can cause discomfort or pain.
Pharmacy schools are expected to graduate 8,000 student pharmacists in 2026…” [Instagram post]. North American Pharmacist Licensure Examination Passing Rates for 2022-2024 Graduates. National Association of Boards of Pharmacy. January 21, 2025. Accessed June 6, 2025. aacpharmacy. March 12, 2025. Accessed June 6, 2025.
Two novel readouts in 2026 French biopharma Axoltis Pharma is testing an ALS candidate that targets the integrity of the blood brain barrier and neural circuits. The biotech expects to publish phase 2 results in the second quarter of 2026. The study is expected to reach its primary completion in July 2026.
1 The FDA set a Prescription Drug User Fee Act (PDUFA) date of April 28, 2026. The FDA has accepted for review a New Drug Application (NDA) for doravirine/islatravir for adult patients with HIV-1 infection that is virologically suppressed on antiretroviral therapy, Merck announced in a release.
1 The Advisory Committee on Immunization Practices voted to lower the pneumococcal recommendation to 50 years in October 2024. Previously, the vaccination recommendation was for patients 65 years and older, but the CDC Advisory Committee on Immunization Practices (ACIP) voted to lower the recommendation to 50 years in October 2024.
It employs a function-first screening workflow to reveal rare and effective immune targets, thereby fast-tracking the next-generation prophylactics and treatments development. Kling-Select provides a powerful window into the human immune response and accelerates the identification of functional antibodies and novel epitopes.
Some companies are combining mRNA vaccines with programmed cell death protein 1 (PD-1) inhibitors to activate the immune system and elicit tumour-specific T-cell responses. The LNPs provide targeted delivery of the mRNA directly to tumours, resulting in strong immune activation, tumour elimination, and durable immunological responses.
The US Food and Drug Administration (FDA) has approved Takeda’s new immunoglobulin (IG) therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat primary immunodeficiency (PI) in individuals aged two years and above. Credit: HenadziPechan/Shutterstock. Don’t let policy changes catch you off guard.
The technology stabilises viral proteins in their native shape, which may lead to more effective immune responses. Find out more Sanofi’s acquisition adds an early-stage combination vaccine for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), as well as the Molecular Clamp technology.
We drew on our heritage as a blood bank to develop a platform reminiscent of a blood mobile for mobile collection of patients’ immune cells. We feel that the key is being able to collect the cells in the community where the patient lives, rather than burdening the hospital with this procedure.
A decision by the FDA is expected in H1 2026. A single dose of the vaccine in adults aged 18-49 at increased risk of RSV-LRTD elicited robust immune responses that were non-inferior to those observed in adults aged 60 and above. FDA approvals do not automatically mean shots enter national immunisation schedules.
LaNova’s drug development focuses on tumour immunity and the tumour microenvironment. Sino revealed the acquisition agreement after trading hours on 15 July. The share price in the company had climbed 3.6% by market close. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?
Danish dermatology leader LEO Pharma has bought the rights to Boehringer Ingelheim’s psoriasis drug Spevigo (spesolimab) for €90m ($105m), strengthening its portfolio ahead of a possible public listing in 2026. It has also been approved in expanded indications in GPP in certain territories.
Neither the White House nor the EC responded to Pharmaceutical Technology when asked which generics would be immune to the agreement. Whilst the tariff rate is a blanket levy that applies to branded products, certain generic drugs will be exempt.
This approval was supported by results from Moderna’s Phase III study (NCT06067230), which demonstrated the vaccine’s immune response worked just as well in this age group compared to the existing approved age group of 60 years and older. The expanded approval now includes individuals aged 18 to 59 who are at risk of RSV.
Investigators expect midpoint data in the third quarter of 2025 and 6-month data in the second half of 2026. Further, from 1 month to 3 months, there was little to no weight change, with a median weight gain at 1 month being 0.43% compared with 0.46% at 3 months. 1 REFERENCES 1.
1 The company said it plans to initiate phase 3 studies in 2026 to further evaluate the therapy. Positive results have been announced from a phase 2a clinical trial evaluating the safety, pharmacokinetics and efficacy of PP405 for the treatment of androgenetic alopecia in adult patients, Pelage Pharmaceuticals announced in a release.
In a controversial move on 9 June 2025, US Secretary of Health and Human Services Robert F Kennedy Jr dismissed all 17 members of the Centers for Disease Control and Prevention (CDC) Advisory Committee for Immunization Practices (ACIP) that advises the federal government on vaccine safety.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content